Why “Just Compound It” Is Not Always the Right Answer
“Just compound it” sounds like a simple solution.
And sometimes, it is.
The patient will not take tablets. The dose does not exist. The formulation is wrong for the species. The route is impractical. Compounding feels like the fastest way to make the plan work.
The problem is not compounding.
The problem is when it becomes the default instead of a decision.
Compounding exists because veterinary medicine needs it. We do not have the depth of approved products that human medicine does, especially for cats, exotics, and less common conditions. In many cases, there is no other option.
But compounding is not a neutral substitution.
Every time you choose a compounded product, you are trading certainty for flexibility.
Approved drugs come with known absorption, validated stability, defined expiration, and predictable performance. Compounded products do not. They depend on formulation, ingredients, technique, and assumptions about how that drug will behave in a completely different dosage form.
Most of the time, that tradeoff is reasonable.
Sometimes, it is not.
One of the most common mistakes is assuming all drugs compound equally well.
They do not.
Some drugs are highly sensitive to formulation. Poor solubility, instability, or reliance on specific delivery systems can make compounded versions unreliable. Itraconazole is a classic example. When compounded from bulk powder without the solubilizing components used in approved products, absorption becomes inconsistent and often inadequate.
The issue is not the dose.
It is the formulation.
So you can increase the dose, switch therapies, or assume treatment failure, when the real problem is that the drug never had a chance to work.
Stability creates a similar problem.
Many compounded preparations degrade faster than expected, even when stored appropriately. Beyond-use dates are not the same as expiration dates. They are estimates, often based on limited data. When we dispense these for longer durations, we can end up treating with medication that is no longer reliable.
That does not look like a formulation issue.
It looks like a patient that is not responding.
Route of administration adds another layer.
Transdermal formulations are often used to make medications easier to give, especially in cats. In a small number of cases, that works well. In many others, it does not. Drugs that require higher doses or consistent systemic exposure often do not absorb adequately through the skin.
Gabapentin is a good example. It is commonly compounded transdermally, but pharmacokinetic data repeatedly show low or undetectable levels in many patients.
It feels easier.
It just may not be effective.
There are also boundaries that matter.
Compounding is not intended to replace an appropriate approved product simply because it is cheaper. That is not just a regulatory issue. It reflects a clinical principle. When a reliable, approved option exists and works for the patient, it usually carries less risk than a customized alternative.
None of this means compounding is wrong.
It means it should be intentional.
The question is not “Can I compound this?”
It is “Should I?”
Because compounding is one of the most powerful tools we have in veterinary medicine.
But like most powerful tools, it works best when it is used deliberately.
Not automatically.